Anderlecht

• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep … Recruiting
  2024-513586-39-00 5 2025-12-10 Prostate Cancer
• A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System … Recruiting
  2024-519493-39-00 5 2025-12-09 High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alt
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• A clinical study to test if an investigational treatment called BNT326 is safe and potentially beneficial when used alone or in combination … Recruiting
  2024-517261-16-00 9 2025-12-05 Advanced solid tumors
• A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in pa … Recruiting
  2024-511392-15-00 5 2025-11-20 HR+/HER2- advanced breast cancer
• Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting
  2025-520555-89-00 5 2025-11-14 Metastatic castration-resistant prostate cancer (mCRPC)
• A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) ( PREVAIL ) Recruiting
  2024-519345-30-00 5 2025-11-12 IgA nephropathy
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan … Recruiting
  2025-520566-22-00 5 2025-11-10 Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
• Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia at high risk of Acute Pancreatitis (SHASTA-5 Study) Recruiting
  2024-518206-40-00 5 2025-11-03 Severe hypertriglyceridemia (SHTG)
• Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI … Recruiting
  2024-514693-47-01 11 2025-10-28 EGFR mutated locally advanced or metastatic non-small cell lung cancer
• EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure … Recruiting
  2025-521188-11-00 5 2025-10-15 Type 2 diabetes
• A research study to evaluate how well etavopivat works in people with sickle cell disease - Hibiscus 2 Recruiting
  2023-509175-16-00 5 2025-10-14 Sickle cell disease
• A Phase 1/2, Multicenter, Open Label, Dose Escalation and Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unre … Recruiting
  2024-512421-92-00 7 2025-10-14 Unresectable, Locally Advanced or Metastatic Cancer
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• A Study to Learn About a Study Medicine Called Ibuzatrelvir in People With Coronavirus Disease 2019 (COVID-19) and a Severely Compromised Im … Recruiting
  2024-517671-21-00 5 2025-09-30 Coronavirus Disease 2019 (COVID-19)
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight: … Recruiting
  2024-520210-21-00 5 2025-09-19 Crohn’s Disease
• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) Recruiting
  2024-513613-12-00 9 2025-09-18 Part A: Healthy volunteers (Part A is not applicable to the EU; for in
• Study of Ruxolitinib Cream in Participants with Hidradenitis Suppurativa (TRuE-HS2) Recruiting
  2024-517633-40-00 5 2025-09-18 Hidradenitis Suppurativa
• A study to evaluate the efficacy and safety of ruxolitinib cream in children (6 to <12 years old) with non-segmental vitiligo Recruiting
  2024-513171-41-00 5 2025-09-11 Vitiligo
• An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR compared to Mexiletine IR in Patients wi … Recruiting
  2024-514970-27-00 5 2025-09-03 Non-Dystrophic Myotonias (NDM)
• Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting
  2024-518154-16-00 5 2025-08-27 non-small cell lung cancer
• A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn’s Disease (CD) Recruiting
  2024-518914-18-00 4 2025-08-27 Moderate to Severely Active Ulcerative Colitis & Moderate to Severely
• A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) Recruiting
  2024-517529-26-00 5 2025-08-04 Chronic Inflammatory Demyelinating Polyneuropathy
• A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph … Recruiting
  2023-509630-19-00 5 2025-07-31 Esophageal Squamous Cell Carcinoma (ESCC)

Showing 97–120 of 445 trials